Group items tagged

Lorcaserin is one of the most advanced antiobesity drugs in clinical development; two others include Qnexa and Contrave. With late-stage trials having reported results for each of these drugs this year, many analysts are sceptical that lorcaserin will be approved by authorities, as major trial results indicate this drug may only just meet the FDA criterion for weight management.